Form 4: Tyra Biosciences Director, Robert J. More, Acquires Stock Options

Director Robert J. More acquired stock options in Tyra Biosciences, Inc. on May 29, 2024, as part of the Non-Employee Director Compensation Program.

Summary

• Robert J. More, a director of Tyra Biosciences, Inc., filed a Form 4 on May 31, 2024, reporting a transaction.
• On May 29, 2024, More acquired 18,600 stock options with an exercise price of $15.94.
• These options were granted as part of the Issuer's Non-Employee Director Compensation Program.
• The options vest monthly, with 1/12th of the total shares vesting each month following the grant date.
• Any remaining unvested options will vest on the date of the next annual meeting of the Issuer's stockholders if it occurs before the first anniversary of the grant date, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to stock option grants, which is generally neutral in sentiment. It reflects standard compensation practices.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This filing is a routine disclosure related to director compensation, which is a common practice in publicly traded companies to incentivize and retain board members.

Comparison to Industry Standards

• Director compensation packages often include stock options to align director interests with shareholder value.
• The vesting schedule described is typical for stock option grants, encouraging long-term commitment.
• Comparable companies in the biotechnology sector, such as Relay Therapeutics and Black Diamond Therapeutics, also utilize stock options as part of their director compensation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates